Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

An Allosteric Anti-tryptase Antibody for the Treatment of Mast Cell-Mediated Severe Asthma.

Maun HR, Jackman JK, Choy DF, Loyet KM, Staton TL, Jia G, Dressen A, Hackney JA, Bremer M, Walters BT, Vij R, Chen X, Trivedi NN, Morando A, Lipari MT, Franke Y, Wu X, Zhang J, Liu J, Wu P, Chang D, Orozco LD, Christensen E, Wong M, Corpuz R, Hang JQ, Lutman J, Sukumaran S, Wu Y, Ubhayakar S, Liang X, Schwartz LB, Babina M, Woodruff PG, Fahy JV, Ahuja R, Caughey GH, Kusi A, Dennis MS, Eigenbrot C, Kirchhofer D, Austin CD, Wu LC, Koerber JT, Lee WP, Yaspan BL, Alatsis KR, Arron JR, Lazarus RA, Yi T.

Cell. 2019 Oct 3;179(2):417-431.e19. doi: 10.1016/j.cell.2019.09.009.

PMID:
31585081
2.

Rare Protein-altering Telomere-related Gene Variants in Patients with Chronic Hypersensitivity Pneumonitis.

Ley B, Torgerson DG, Oldham JM, Adegunsoye A, Liu S, Li J, Elicker BM, Henry TS, Golden JA, Jones KD, Dressen A, Yaspan BL, Arron JR, Noth I, Hoffmann TJ, Wolters PJ.

Am J Respir Crit Care Med. 2019 Jul 3. doi: 10.1164/rccm.201902-0360OC. [Epub ahead of print]

PMID:
31268371
3.

TAZ is required for lung alveolar epithelial cell differentiation after injury.

Sun T, Huang Z, Zhang H, Posner C, Jia G, Ramalingam TR, Xu M, Brightbill H, Egen JG, Dey A, Arron JR.

JCI Insight. 2019 Jun 18;5. pii: 128674. doi: 10.1172/jci.insight.128674.

4.

Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials.

Neighbors M, Cabanski CR, Ramalingam TR, Sheng XR, Tew GW, Gu C, Jia G, Peng K, Ray JM, Ley B, Wolters PJ, Collard HR, Arron JR.

Lancet Respir Med. 2018 Aug;6(8):615-626. doi: 10.1016/S2213-2600(18)30185-1. Epub 2018 Jun 29.

PMID:
30072107
5.

Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study.

Dressen A, Abbas AR, Cabanski C, Reeder J, Ramalingam TR, Neighbors M, Bhangale TR, Brauer MJ, Hunkapiller J, Reeder J, Mukhyala K, Cuenco K, Tom J, Cowgill A, Vogel J, Forrest WF, Collard HR, Wolters PJ, Kropski JA, Lancaster LH, Blackwell TS, Arron JR, Yaspan BL.

Lancet Respir Med. 2018 Aug;6(8):603-614. doi: 10.1016/S2213-2600(18)30135-8. Epub 2018 Jun 18.

6.

Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD).

Khoury P, Akuthota P, Ackerman SJ, Arron JR, Bochner BS, Collins MH, Kahn JE, Fulkerson PC, Gleich GJ, Gopal-Srivastava R, Jacobsen EA, Leiferman KM, Francesca LS, Mathur SK, Minnicozzi M, Prussin C, Rothenberg ME, Roufosse F, Sable K, Simon D, Simon HU, Spencer LA, Steinfeld J, Wardlaw AJ, Wechsler ME, Weller PF, Klion AD.

J Leukoc Biol. 2018 Jul;104(1):69-83. doi: 10.1002/JLB.5MR0118-028R. Epub 2018 Apr 19. Review.

7.

Airway pathological heterogeneity in asthma: Visualization of disease microclusters using topological data analysis.

Siddiqui S, Shikotra A, Richardson M, Doran E, Choy D, Bell A, Austin CD, Eastham-Anderson J, Hargadon B, Arron JR, Wardlaw A, Brightling CE, Heaney LG, Bradding P.

J Allergy Clin Immunol. 2018 Nov;142(5):1457-1468. doi: 10.1016/j.jaci.2017.12.982. Epub 2018 Mar 14.

PMID:
29550052
8.

A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial.

Hanratty CE, Matthews JG, Arron JR, Choy DF, Pavord ID, Bradding P, Brightling CE, Chaudhuri R, Cowan DC, Djukanovic R, Gallagher N, Fowler SJ, Hardman TC, Harrison T, Holweg CT, Howarth PH, Lordan J, Mansur AH, Menzies-Gow A, Mosesova S, Niven RM, Robinson DS, Shaw DE, Walker S, Woodcock A, Heaney LG; RASP-UK (Refractory Asthma Stratification Programme) Consortium.

Trials. 2018 Jan 4;19(1):5. doi: 10.1186/s13063-017-2384-7.

9.

IFN-stimulated Gene Expression, Type 2 Inflammation, and Endoplasmic Reticulum Stress in Asthma.

Bhakta NR, Christenson SA, Nerella S, Solberg OD, Nguyen CP, Choy DF, Jung KL, Garudadri S, Bonser LR, Pollack JL, Zlock LT, Erle DJ, Langelier C, Derisi JL, Arron JR, Fahy JV, Woodruff PG.

Am J Respir Crit Care Med. 2018 Feb 1;197(3):313-324. doi: 10.1164/rccm.201706-1070OC.

10.

Interleukin-13 in Asthma and Other Eosinophilic Disorders.

Doran E, Cai F, Holweg CTJ, Wong K, Brumm J, Arron JR.

Front Med (Lausanne). 2017 Sep 19;4:139. doi: 10.3389/fmed.2017.00139. eCollection 2017.

11.

Type 2 immunity is protective in metabolic disease but exacerbates NAFLD collaboratively with TGF-β.

Hart KM, Fabre T, Sciurba JC, Gieseck RL 3rd, Borthwick LA, Vannella KM, Acciani TH, de Queiroz Prado R, Thompson RW, White S, Soucy G, Bilodeau M, Ramalingam TR, Arron JR, Shoukry NH, Wynn TA.

Sci Transl Med. 2017 Jun 28;9(396). pii: eaal3694. doi: 10.1126/scitranslmed.aal3694.

PMID:
28659437
12.

Increased Autophagy-Related 5 Gene Expression Is Associated with Collagen Expression in the Airways of Refractory Asthmatics.

Poon AH, Choy DF, Chouiali F, Ramakrishnan RK, Mahboub B, Audusseau S, Mogas A, Harris JM, Arron JR, Laprise C, Hamid Q.

Front Immunol. 2017 Mar 29;8:355. doi: 10.3389/fimmu.2017.00355. eCollection 2017.

13.

Accurately measuring and modeling Th2 and Th17 endotypes in severe asthma.

Hart KM, Choy DF, Bradding P, Wynn TA, Arron JR.

Ann Transl Med. 2017 Feb;5(4):91. doi: 10.21037/atm.2017.02.07. No abstract available.

14.

A CEACAM6-High Airway Neutrophil Phenotype and CEACAM6-High Epithelial Cells Are Features of Severe Asthma.

Shikotra A, Choy DF, Siddiqui S, Arthur G, Nagarkar DR, Jia G, Wright AK, Ohri CM, Doran E, Butler CA, Hargadon B, Abbas AR, Jackman J, Wu LC, Heaney LG, Arron JR, Bradding P.

J Immunol. 2017 Apr 15;198(8):3307-3317. doi: 10.4049/jimmunol.1600606. Epub 2017 Mar 8.

15.

CXCL14 is a candidate biomarker for Hedgehog signalling in idiopathic pulmonary fibrosis.

Jia G, Chandriani S, Abbas AR, DePianto DJ, N'Diaye EN, Yaylaoglu MB, Moore HM, Peng I, DeVoss J, Collard HR, Wolters PJ, Egen JG, Arron JR.

Thorax. 2017 Sep;72(9):780-787. doi: 10.1136/thoraxjnl-2015-207682. Epub 2017 Mar 1.

PMID:
28250200
16.

Seasonal variability of severe asthma exacerbations and clinical benefit from lebrikizumab.

Staton TL, Arron JR, Olsson J, Holweg CTJ, Matthews JG, Choy DF.

J Allergy Clin Immunol. 2017 May;139(5):1682-1684.e3. doi: 10.1016/j.jaci.2017.01.028. Epub 2017 Feb 24. No abstract available.

PMID:
28238745
17.

IL-13 is a therapeutic target in radiation lung injury.

Chung SI, Horton JA, Ramalingam TR, White AO, Chung EJ, Hudak KE, Scroggins BT, Arron JR, Wynn TA, Citrin DE.

Sci Rep. 2016 Dec 22;6:39714. doi: 10.1038/srep39714.

18.

Fit-for-purpose biomarker immunoassay qualification and validation: three case studies.

Cowan K, Gao X, Parab V, Nguy T, Wu L, Arron JR, Townsend M, Wallin J, Cheu M, Morimoto A, Wakshull E.

Bioanalysis. 2016 Nov;8(22):2329-2340. doi: 10.4155/bio-2016-0184. Epub 2016 Oct 7.

PMID:
27712082
19.

Depletion of major pathogenic cells in asthma by targeting CRTh2.

Huang T, Hazen M, Shang Y, Zhou M, Wu X, Yan D, Lin Z, Solon M, Luis E, Ngu H, Shi Y, Katewa A, Choy DF, Ramamoorthi N, Castellanos ER, Balazs M, Xu M, Lee WP, Matsumoto ML, Payandeh J, Arron JR, Hongo JA, Wang J, Hötzel I, Austin CD, Reif K.

JCI Insight. 2016 May 19;1(7):e86689. doi: 10.1172/jci.insight.86689.

20.

Relationships among aeroallergen sensitization, peripheral blood eosinophils, and periostin in pediatric asthma development.

Anderson HM, Lemanske RF Jr, Arron JR, Holweg CTJ, Rajamanickam V, Gangnon RE, Gern JE, Jackson DJ.

J Allergy Clin Immunol. 2017 Mar;139(3):790-796. doi: 10.1016/j.jaci.2016.05.033. Epub 2016 Jul 5.

21.

Peripheral blood gene expression predicts clinical benefit from anti-IL-13 in asthma.

Choy DF, Jia G, Abbas AR, Morshead KB, Lewin-Koh N, Dua R, Rivera P, Moonsamy P, Fontecha M, Balasubramanyam A, Santini C, Bassett E, Ray JM, Cabanski CR, Bradley MS, Maciuca R, Mosesova S, Scheerens H, Arron JR.

J Allergy Clin Immunol. 2016 Oct;138(4):1230-1233.e8. doi: 10.1016/j.jaci.2016.06.008. Epub 2016 Jun 29. No abstract available.

PMID:
27474124
22.

Reducing the risk of failure: biomarker-guided trial design.

Townsend MJ, Arron JR.

Nat Rev Drug Discov. 2016 Aug;15(8):517-8. doi: 10.1038/nrd.2016.124. Epub 2016 Jul 15. No abstract available.

PMID:
27417848
23.

Reduced epithelial suppressor of cytokine signalling 1 in severe eosinophilic asthma.

Doran E, Choy DF, Shikotra A, Butler CA, O'Rourke DM, Johnston JA, Kissenpfennig A, Bradding P, Arron JR, Heaney LG.

Eur Respir J. 2016 Sep;48(3):715-25. doi: 10.1183/13993003.00400-2015. Epub 2016 Jun 23.

24.

Biomarkers in the clinical development of asthma therapies.

Staton TL, Choy DF, Arron JR.

Biomark Med. 2016;10(2):165-76. doi: 10.2217/bmm.15.116. Epub 2016 Jan 14. Review.

PMID:
26764286
25.

Roles of Periostin in Respiratory Disorders.

Izuhara K, Conway SJ, Moore BB, Matsumoto H, Holweg CT, Matthews JG, Arron JR.

Am J Respir Crit Care Med. 2016 May 1;193(9):949-56. doi: 10.1164/rccm.201510-2032PP. Review.

26.

Reply.

Huang YJ, Arron JR, Boushey H.

J Allergy Clin Immunol. 2016 Feb;137(2):648-9. doi: 10.1016/j.jaci.2015.09.044. Epub 2015 Dec 10. No abstract available.

PMID:
26684292
27.

Inhibition of the kinase ITK in a mouse model of asthma reduces cell death and fails to inhibit the inflammatory response.

Sun Y, Peng I, Webster JD, Suto E, Lesch J, Wu X, Senger K, Francis G, Barrett K, Collier JL, Burch JD, Zhou M, Chen Y, Chan C, Eastham-Anderson J, Ngu H, Li O, Staton T, Havnar C, Jaochico A, Jackman J, Jeet S, Riol-Blanco L, Wu LC, Choy DF, Arron JR, McKenzie BS, Ghilardi N, Ismaili MH, Pei Z, DeVoss J, Austin CD, Lee WP, Zarrin AA.

Sci Signal. 2015 Dec 1;8(405):ra122. doi: 10.1126/scisignal.aab0949.

PMID:
26628680
28.

TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma.

Choy DF, Hart KM, Borthwick LA, Shikotra A, Nagarkar DR, Siddiqui S, Jia G, Ohri CM, Doran E, Vannella KM, Butler CA, Hargadon B, Sciurba JC, Gieseck RL, Thompson RW, White S, Abbas AR, Jackman J, Wu LC, Egen JG, Heaney LG, Ramalingam TR, Arron JR, Wynn TA, Bradding P.

Sci Transl Med. 2015 Aug 19;7(301):301ra129. doi: 10.1126/scitranslmed.aab3142.

PMID:
26290411
29.

The airway microbiome in patients with severe asthma: Associations with disease features and severity.

Huang YJ, Nariya S, Harris JM, Lynch SV, Choy DF, Arron JR, Boushey H.

J Allergy Clin Immunol. 2015 Oct;136(4):874-84. doi: 10.1016/j.jaci.2015.05.044. Epub 2015 Jul 26.

30.

Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK).

Heaney LG, Djukanovic R, Woodcock A, Walker S, Matthews JG, Pavord ID, Bradding P, Niven R, Brightling CE, Chaudhuri R, Arron JR, Choy DF, Cowan D, Mansur A, Menzies-Gow A, Adcock I, Chung KF, Corrigan C, Coyle P, Harrison T, Johnston S, Howarth P, Lordan J, Sabroe I, Bigler J, Smith D, Catley M, May R, Pierre L, Stevenson C, Crater G, Keane F, Costello RW, Hudson V, Supple D, Hardman T.

Thorax. 2016 Feb;71(2):187-9. doi: 10.1136/thoraxjnl-2015-207326. Epub 2015 Jul 23. Review.

31.

Stratified medicine in inflammatory disorders: From theory to practice.

Arron JR, Townsend MJ, Keir ME, Yaspan BL, Chan AC.

Clin Immunol. 2015 Nov;161(1):11-22. doi: 10.1016/j.clim.2015.04.006. Epub 2015 Apr 28. Review.

PMID:
25934386
32.

IL-13 mediates IL-33-dependent mast cell and type 2 innate lymphoid cell effects on bronchial epithelial cells.

Nagarkar DR, Ramirez-Carrozzi V, Choy DF, Lee K, Soriano R, Jia G, Abbas AR, Modrusan Z, Pappu R, Arron JR.

J Allergy Clin Immunol. 2015 Jul;136(1):202-5. doi: 10.1016/j.jaci.2015.01.036. Epub 2015 Mar 14. No abstract available.

PMID:
25784274
33.

Asthma biomarkers: what constitutes a 'gold standard'?

Arron JR, Izuhara K.

Thorax. 2015 Feb;70(2):105-7. doi: 10.1136/thoraxjnl-2014-206069. Epub 2014 Nov 28. No abstract available.

PMID:
25432945
34.

A microRNA upregulated in asthma airway T cells promotes TH2 cytokine production.

Simpson LJ, Patel S, Bhakta NR, Choy DF, Brightbill HD, Ren X, Wang Y, Pua HH, Baumjohann D, Montoya MM, Panduro M, Remedios KA, Huang X, Fahy JV, Arron JR, Woodruff PG, Ansel KM.

Nat Immunol. 2014 Dec;15(12):1162-70. doi: 10.1038/ni.3026. Epub 2014 Nov 2.

35.

Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis.

DePianto DJ, Chandriani S, Abbas AR, Jia G, N'Diaye EN, Caplazi P, Kauder SE, Biswas S, Karnik SK, Ha C, Modrusan Z, Matthay MA, Kukreja J, Collard HR, Egen JG, Wolters PJ, Arron JR.

Thorax. 2015 Jan;70(1):48-56. doi: 10.1136/thoraxjnl-2013-204596. Epub 2014 Sep 12.

36.

Endogenously expressed IL-13Rα2 attenuates IL-13-mediated responses but does not activate signaling in human lung fibroblasts.

Chandriani S, DePianto DJ, N'Diaye EN, Abbas AR, Jackman J, Bevers J 3rd, Ramirez-Carrozzi V, Pappu R, Kauder SE, Toy K, Ha C, Modrusan Z, Wu LC, Collard HR, Wolters PJ, Egen JG, Arron JR.

J Immunol. 2014 Jul 1;193(1):111-9. doi: 10.4049/jimmunol.1301761. Epub 2014 May 30.

37.

Interleukin-18 has antipermeablity and antiangiogenic activities in the eye: reciprocal suppression with VEGF.

Shen J, Choy DF, Yoshida T, Iwase T, Hafiz G, Xie B, Hackett SF, Arron JR, Campochiaro PA.

J Cell Physiol. 2014 Aug;229(8):974-83. doi: 10.1002/jcp.24575.

38.

Noninvasive biomarkers that predict treatment benefit from biologic therapies in asthma.

Arron JR, Choy DF, Scheerens H, Matthews JG.

Ann Am Thorac Soc. 2013 Dec;10 Suppl:S206-13. doi: 10.1513/AnnalsATS.201303-047AW. Review.

PMID:
24313774
39.

Disconnect between sputum neutrophils and other measures of airway inflammation in asthma.

Arron JR, Choy DF, Laviolette M, Kelsen SG, Hatab A, Leigh R, Thomson NC, Bleecker ER, Olivenstein R, Avila PC, Jarjour NN, Castro M, Gauvreau GM, Good JT, Kline JN, Mansur A, Mayers I, Heaney LG, Hamid Q, Harris JM.

Eur Respir J. 2014 Feb;43(2):627-9. doi: 10.1183/09031936.00117013. Epub 2013 Oct 31. No abstract available.

40.

The role of periostin in tissue remodeling across health and disease.

Conway SJ, Izuhara K, Kudo Y, Litvin J, Markwald R, Ouyang G, Arron JR, Holweg CT, Kudo A.

Cell Mol Life Sci. 2014 Apr;71(7):1279-88. doi: 10.1007/s00018-013-1494-y. Epub 2013 Oct 22. Review.

41.

The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge.

Scheerens H, Arron JR, Zheng Y, Putnam WS, Erickson RW, Choy DF, Harris JM, Lee J, Jarjour NN, Matthews JG.

Clin Exp Allergy. 2014 Jan;44(1):38-46. doi: 10.1111/cea.12220.

42.

A qPCR-based metric of Th2 airway inflammation in asthma.

Bhakta NR, Solberg OD, Nguyen CP, Nguyen CN, Arron JR, Fahy JV, Woodruff PG.

Clin Transl Allergy. 2013 Jul 17;3(1):24. doi: 10.1186/2045-7022-3-24.

43.

Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids.

Noonan M, Korenblat P, Mosesova S, Scheerens H, Arron JR, Zheng Y, Putnam WS, Parsey MV, Bohen SP, Matthews JG.

J Allergy Clin Immunol. 2013 Sep;132(3):567-574.e12. doi: 10.1016/j.jaci.2013.03.051. Epub 2013 May 29.

PMID:
23726041
44.

Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study.

Hanania NA, Wenzel S, Rosén K, Hsieh HJ, Mosesova S, Choy DF, Lal P, Arron JR, Harris JM, Busse W.

Am J Respir Crit Care Med. 2013 Apr 15;187(8):804-11. doi: 10.1164/rccm.201208-1414OC.

PMID:
23471469
45.

Redefining approaches to asthma: developing targeted biologic therapies.

Arron JR, Scheerens H, Matthews JG.

Adv Pharmacol. 2013;66:1-49. doi: 10.1016/B978-0-12-404717-4.00001-9. Review.

PMID:
23433454
46.

Airway epithelial miRNA expression is altered in asthma.

Solberg OD, Ostrin EJ, Love MI, Peng JC, Bhakta NR, Hou L, Nguyen C, Solon M, Nguyen C, Barczak AJ, Zlock LT, Blagev DP, Finkbeiner WE, Ansel KM, Arron JR, Erle DJ, Woodruff PG.

Am J Respir Crit Care Med. 2012 Nov 15;186(10):965-74. doi: 10.1164/rccm.201201-0027OC. Epub 2012 Sep 6.

47.

Comparative transcriptomic analyses of atopic dermatitis and psoriasis reveal shared neutrophilic inflammation.

Choy DF, Hsu DK, Seshasayee D, Fung MA, Modrusan Z, Martin F, Liu FT, Arron JR.

J Allergy Clin Immunol. 2012 Dec;130(6):1335-43.e5. doi: 10.1016/j.jaci.2012.06.044. Epub 2012 Aug 22.

48.

Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients.

Jia G, Erickson RW, Choy DF, Mosesova S, Wu LC, Solberg OD, Shikotra A, Carter R, Audusseau S, Hamid Q, Bradding P, Fahy JV, Woodruff PG, Harris JM, Arron JR; Bronchoscopic Exploratory Research Study of Biomarkers in Corticosteroid-refractory Asthma (BOBCAT) Study Group.

J Allergy Clin Immunol. 2012 Sep;130(3):647-654.e10. doi: 10.1016/j.jaci.2012.06.025. Epub 2012 Aug 1.

49.

Glucocorticoid receptor β and histone deacetylase 1 and 2 expression in the airways of severe asthma.

Butler CA, McQuaid S, Taggart CC, Weldon S, Carter R, Skibinski G, Warke TJ, Choy DF, McGarvey LP, Bradding P, Arron JR, Heaney LG.

Thorax. 2012 May;67(5):392-8. doi: 10.1136/thoraxjnl-2011-200760. Epub 2011 Dec 8.

PMID:
22156779
50.

Increased expression of immunoreactive thymic stromal lymphopoietin in patients with severe asthma.

Shikotra A, Choy DF, Ohri CM, Doran E, Butler C, Hargadon B, Shelley M, Abbas AR, Austin CD, Jackman J, Wu LC, Heaney LG, Arron JR, Bradding P.

J Allergy Clin Immunol. 2012 Jan;129(1):104-11.e1-9. doi: 10.1016/j.jaci.2011.08.031. Epub 2011 Oct 5.

PMID:
21975173

Supplemental Content

Loading ...
Support Center